About

Autophagy represents a new frontier of drug discovery. Casma is building a team of dedicated individuals who share a passion to advance new treatments to cure challenging diseases while creating a culture of trust, risk-taking and teamwork.”

Keith Dionne, Ph.D.
Chief Executive Officer

New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today.

Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.

Investors

Third Rock

Third Rock Ventures is a leading health care venture firm focused on investing in, launching and building companies that make a difference in people’s lives. Third Rock collaborates closely with its strategic partners and entrepreneurs and has an extensive track record of managing value creation to deliver exceptional performance.

Collaborators

Tigem

The Telethon Institute of Genetics and Medicine (TIGEM) is a multidisciplinary research institute devoted to the study of the mechanisms underlying rare genetic diseases and to the development of new therapies. The institute employs 200 Italian and foreign researchers in 20 independent research groups. Founded in 1994 by the Fondazione Telethon and located in Pozzuoli (Naples), the institute is one of the most important centers for fundamental life science research in Italy.